Table of contents
Nguyen Injury Lawyer is actively investigating potential Tepezza hearing loss lawsuits across the country. This page provides an overview of Tepezza litigation, including possible settlement timelines and potential compensation for individuals who have experienced hearing loss or tinnitus after Tepezza injections for Thyroid Eye Disease (TED). If you have suffered hearing damage after Tepezza treatment, you may be eligible to file a product liability lawsuit and receive financial compensation. Our attorneys are currently reviewing Tepezza hearing damage claims.
We are strong believers in these lawsuits. While we cannot guarantee any specific outcome, we are optimistic about the possibility of favorable settlements, potentially even before the first Tepezza case goes to trial. This page will be regularly updated with the latest news and developments in the Tepezza litigation, along with our insights on the potential settlement value of these cases.
Contact Nguyen Injury Lawyer today at XXX-XXX-XXXX or through our online contact form at https://www.nguyeninjurylawyer.com/contact for a free, no-obligation consultation to discuss your case.
Tepezza Lawsuit Updates
Nguyen Injury Lawyer is committed to keeping you informed about the progress of the Tepezza lawsuits as new information becomes available. Here are the latest updates:
January 6, 2026
As of January 2026, the Tepezza hearing loss MDL (multidistrict litigation) includes 273 pending cases, with a total of 282 cases filed.
December 9, 2025
The Tepezza hearing loss litigation continues to expand, although at a slower rate. In November, only one new case was added, bringing the total number of pending cases in the MDL to 273. While the current rate of new filings is modest, the consistent addition of claims suggests that more cases may arise as awareness of the potential risks grows.
November 4, 2025
No new cases were added to the Tepezza MDL last month, leaving the total number of pending cases at 272.
October 2, 2025
This MDL continues its gradual growth, with the addition of two new cases, bringing the total to 272. The status hearing that was scheduled for yesterday has been canceled. Instead, the attorneys will hold a phone conference with the court by contacting the courtroom deputy via email to discuss the current status of the litigation.
September 21, 2025
The Tepezza hearing loss MDL has added 10 new cases since last month, increasing the total number of pending lawsuits from 260 to 270 as of early September.
There has also been activity behind the scenes: the court has granted a 45-day extension for expert deposition deadlines, which has subsequently pushed back the dates for summary judgment motions and other trial preparation milestones. The bellwether trials remain scheduled, with the first trial set for June 2026 and subsequent trials in August, September, and November 2026.
August 22, 2025
The first Tepezza hearing loss bellwether trial has been rescheduled to August 3, 2026, with additional trials scheduled for September 28, 2026, November 30, 2026, and February 1, 2027. Each trial is expected to last approximately three to four weeks.
August 17, 2025
There are currently 260 Tepezza lawsuits consolidated in the MDL.
August 2, 2025
In a recent lawsuit filed in the MDL in the Northern District of Illinois, an Indiana woman alleges that she suffered permanent hearing loss and tinnitus after receiving Tepezza infusions. She claims that her injuries were a direct result of Horizon Therapeutics’ decision to withhold critical safety information about its thyroid eye disease drug, despite growing evidence of serious risks.
The plaintiff’s experience followed a common pattern. She was diagnosed with thyroid eye disease, offered what was promoted as a breakthrough therapy, and ultimately suffered life-altering harm that she was not warned about. From July 2021 through January 2022, she received Tepezza infusions in Indiana.
At the time, the drug’s label did not include any warnings about permanent hearing loss or tinnitus, and there were no recommendations for audiological monitoring. This only changed in July 2023, well after her treatment had ended, when Horizon revised the label to acknowledge the risk of severe and potentially permanent hearing impairment.
The lawsuit focuses on Horizon’s alleged failure to act when it had reason to do so. Data from internal studies, including an expanded access program known as Study 401, reportedly showed hearing-related adverse events in up to 40 percent of patients. These results were allegedly known as early as March 2020.
However, Horizon allegedly waited years to update the label and chose a slower regulatory path instead of taking immediate steps to warn the public through a CBE label change. A whistleblower who raised these concerns within the company was allegedly terminated.
July 21, 2025
The Tepezza multidistrict litigation is progressing with a revised schedule that pushes key deadlines and trial dates into mid-to-late 2026.
Expert discovery has been rescheduled, with plaintiffs’ expert depositions now scheduled to take place between August 25 and September 19, 2025, followed by the defendants’ expert disclosures and depositions running through October 17, 2025. Critical Rule 702 motions—challenges to the admissibility of expert testimony—will now be fully briefed by January 9, 2026, with oral arguments expected the week of January 19–23. The court aims to issue rulings on those motions by February 9, 2026, setting the stage for summary judgment.
Summary judgment motions in the first four bellwether cases are due by February 6, 2026, with opposition briefs due March 2 and replies by March 20. If necessary, oral arguments on summary judgment will take place the week of March 28, 2026, and rulings could follow within 60 days. The first bellwether trial is now scheduled to begin June 8, 2026, with subsequent trials staggered through the remainder of the year: August 3, September 28, and November 30, 2026.
The outcomes of these trials will likely influence any global resolution strategy, meaning that a broad settlement is unlikely before late 2026 at the earliest.
July 7, 2025
In a recent lawsuit, a woman from Pahrump, Nevada, has filed claims against Horizon Therapeutics and its corporate successors, alleging that she suffered permanent hearing loss and tinnitus following infusions of Tepezza.
The plaintiff, diagnosed with thyroid eye disease and/or Graves’ disease, began receiving Tepezza treatments in July 2023, before the drug’s label was updated to include warnings about the risk of severe hearing impairment and recommendations for auditory monitoring.
July 2, 2025
There are now 236 active Tepezza lawsuits in the MDL, representing a notable increase in the litigation.
June 27, 2025
Nguyen Injury Lawyer predicts that a Tepezza settlement may be reached in early 2026, before the first bellwether trial begins.
May 1, 2025
There are currently 217 active Tepezza hearing loss lawsuits, up from 213 last month. This represents a modest increase of four cases. It’s important to note that Horizon’s attempt to dismiss the entire litigation was recently denied.
April 9, 2025
The MDL judge denied the plaintiffs’ motion to compel Horizon Therapeutics to produce six Patient Access Liaisons (PALs) and one sales representative for deposition in the Tepezza multidistrict litigation (MDL No. 3079).
The plaintiffs argued that these PALs, who communicated directly with patients about their Tepezza treatment, possessed relevant, case-specific knowledge that should not count against the 30-deposition cap agreed upon in Case Management Order No. 5. They also claimed that when the deposition limits were negotiated, they were unaware of how central PALs would be to the case because meaningful document production had not yet occurred.
The Court disagreed, finding that:
- PALs had been listed as custodians by Horizon as early as August 2023.
- The plaintiffs did not request information about PALs until over a year later.
- The 30-deposition limit applies to all plaintiffs, regardless of which attorneys signed the original stipulation.
- The language cited by plaintiffs regarding case-specific PAL document production did not convert all PAL-related discovery into case-specific depositions.
- Requiring seven more depositions near the close of discovery would place an undue burden on the defendant.
Ultimately, the Court ruled that the plaintiffs had not shown “good cause” under Rule 30 to exceed the agreed deposition limits and denied the motion.
April 1, 2025
The Tepezza hearing loss MDL now includes 207 total lawsuits, up from 203 in early March. Growth remains slow but steady, reflecting the relatively small size of the litigation. However, all eyes are now on the 2026 bellwether trial schedule, which could shift settlement talks into gear. The first of four scheduled trials is set to begin in March 2026, and both sides are currently refining their trial picks from the initial bellwether pool.
March 25, 2025
The first bellwether trials in the litigation, designed to set the stage for how other cases may unfold, will take place in 2026. These trials, which will begin in April and run through September, will help gauge the potential for settlements and shape future litigation strategies. Although the results of these initial trials will not bind other lawsuits, they are expected to heavily influence settlement talks and legal strategies moving forward.
March 4, 2025
The Tepezza hearing loss litigation entered the month of February with 203 cases. There are now 207 cases, reflecting a similar volume of new cases as last month.
January 11, 2025
The number of new cases in the Tepezza hearing loss MDL continues to grow slowly. After adding only 11 new cases in November, just 9 new cases were added in the month of December, bringing the total number of pending cases in the MDL to 200.
December 30, 2024
A hearing for the selection of bellwether test cases has been scheduled for January 28, 2025, in the Tepezza MDL. A group of 12 bellwether “discovery cases” were previously selected back in June, with 4 cases selected by each side and another 4 cases randomly selected by the court. Now, 3 of these cases will be selected for the first round of actual bellwether test trials. Once selected, these 3 cases will undergo a more intensive, case-specific discovery phase to prepare them for trial.
December 2, 2024
The Tepezza hearing loss MDL saw a notable increase in November, with 11 new cases added—a 450% increase from October’s total of just two cases. Nguyen Injury Lawyer believes that settlement may occur sooner in this MDL compared to others, given the relatively small number of claims and the strength of the plaintiffs’ cases.
November 13, 2024
The court addressed the plaintiffs’ motion discussed in our last update and issued a favorable ruling, finding that the defense counsel’s objections were obstructive and unnecessary. The court noted that the defendant’s repeated objections over document foundations were largely misplaced, as documents produced during discovery imply authentication. It also found that another defense attorney could have used a “running objection” rather than repeatedly objecting.
November 4, 2024
In mass tort cases, defense lawyers are expected to limit their objections in depositions to issues of form and foundation. However, the temptation to influence the witness’s testimony, subtly or otherwise, can lead to speaking objections, witness coaching, or repetitive interruptions.
Tepezza Lawsuit Updates
During a recent deposition involving Horizon’s Director of Regulatory Affairs, the legal team for the plaintiffs raised concerns about the defense attorneys’ conduct. They alleged that the defense lawyers repeatedly used speaking objections and improperly coached the witness. According to the plaintiffs’ attorneys, every attempt to question the witness about critical regulatory documents was met with lengthy objections from Horizon’s counsel. These objections challenged the relevance of the documents and the witness’s familiarity with them.
In one instance, defense counsel allegedly interrupted before plaintiffs’ counsel could finish a question, asserting that the documents in question were merely “draft exchanges” not directly related to the defense. The plaintiffs argue that this tactic was a clear attempt to influence the witness’s testimony by implying a limited understanding of the documents.
When plaintiffs’ counsel tried to continue their questioning, the defense allegedly maintained a constant barrage of “foundation” objections, insisting that the documents had not been properly authenticated or confirmed. Nguyen Injury Lawyer believes that if the witness held a significant position in Horizon’s regulatory affairs during Tepezza’s FDA approval process, she should possess knowledge of these documents.
To prevent further occurrences, the plaintiffs’ legal team has filed a motion. If you have questions about the Tepezza litigation, please contact Nguyen Injury Lawyer at XXX-XXX-XXXX. You can also visit our website at https://www.nguyeninjurylawyer.com or use our contact page: https://www.nguyeninjurylawyer.com/contact.
November 1, 2024
The Tepezza MDL continues to grow slowly, with only two new cases added in October, bringing the total to 180 pending cases.
This modest growth highlights the slow rate at which new plaintiffs are joining the litigation. Despite ongoing efforts by plaintiffs’ attorneys to raise awareness, the MDL’s limited expansion suggests that many potential claimants have yet to come forward. Nguyen Injury Lawyer believes there are many more victims who could be part of this action. The attorneys at Nguyen Injury Lawyer believe this litigation probably will not grow all that much.
As we have said before, we believe the small size of the litigation could be a benefit for existing plaintiffs in terms of the speed of the litigation and the potential settlement amounts.
October 29, 2024
Horizon successfully dismissed one of the 12 bellwether cases in the MDL by taking advantage of a now-amended Michigan law. Judge Durkin determined that Michigan law applied to the plaintiff’s claim because she took the drug and experienced the alleged side effects in Michigan, even though the lawsuit was filed in Illinois, where Horizon is based.
Horizon based its argument on a now-repealed Michigan law that prohibited product liability claims against FDA-approved drugs. Although the law has since been corrected, the change is not retroactive.
October 18, 2024
An Oklahoma resident has filed a new lawsuit against Horizon Therapeutics, alleging that Tepezza caused irreversible hearing damage. The plaintiff, who was treated for thyroid eye disease between November 2022 and February 2023, claims that Horizon failed to provide adequate warnings about the risk of permanent hearing loss, despite evidence of the drug’s potential side effects.
This appears to be a strong case. The lawsuit points out that Horizon only updated the Tepezza label to include a warning about severe hearing impairment in July 2023—not long after the plaintiff had already undergone several infusions. It further alleges that Horizon was aware of reports and clinical studies indicating the risk of hearing-related issues well before the warning change.
The plaintiff contends that Horizon’s failure to act on this information earlier directly resulted in significant harm and seeks both compensatory and punitive damages for the company’s alleged negligence in addressing known risks.
October 1, 2024
Only five new cases were added to the Tepezza hearing loss class action MDL during September. There are now 178 pending cases in the MDL. Again, this is not going to be a huge MDL, but our lawyers think these lawsuits have high settlement values.
September 17, 2024
A Florida woman has filed a new lawsuit against Horizon Therapeutics USA, Inc., alleging that the company’s drug, Tepezza, caused her permanent hearing loss. The plaintiff received Tepezza infusions from October 2020 to June 2021 to treat thyroid eye disease.
She claims that Horizon Therapeutics failed to provide adequate warnings about the risks of hearing damage, despite numerous reports and studies linking the drug to permanent hearing impairment and tinnitus. The lawsuit highlights that the Tepezza label did not include warnings about these risks until July 2023, several years after her treatment began.
The plaintiff seeks damages for the injuries she suffered as a result of the company’s alleged failure to properly inform patients and healthcare providers about the potential side effects of Tepezza.
Horizon Therapeutics, which was acquired by Amgen Inc. in 2023, is accused of failing to conduct adequate safety studies and delaying necessary label changes that would have warned of these severe risks. The plaintiff is requesting compensatory and punitive damages for her injuries.
September 3, 2024
In August, 33 new cases were added to the Tepezza hearing loss MDL. That is significantly higher than the normal volume of new cases that we have seen so far in the MDL. There are now 173 total cases pending.
August 18, 2024
The parties have successfully negotiated an agreement regarding the number and scheduling of depositions. According to the Joint Status Report, they have settled on the total number of depositions and divided them into two phases: those to be completed before February 14, 2025, and those to be conducted between this date and April 10, 2025. Additionally, they have reached consensus on various aspects of the deposition process.
Nguyen Injury Lawyer continues to believe these cases will likely settle much quicker than you usually see in an MDL and long before the first bellwether trial in 2026.
August 1, 2024
Growth in the Tepezza MDL continues to be slow. Only 10 new cases were added to the MDL in July, bringing the total number of pending cases up to 148.
Nguyen Injury Lawyer is surprised at how few Tepezza leads we get in 2024, honestly. There are more victims out there on the sidelines. If you have a case, you should call a Tepezza lawyer – preferably us – sooner rather than later.
July 30, 2024
Horizon filed a motion to dismiss that will surely fail. Meanwhile, lawyers for both sides in the Tepezza MDL were scheduled to meet and work out issues regarding the scope and number of corporate and expert witness depositions that would be permitted. The defendants are seeking to limit the number of corporate depositions while the plaintiffs are pushing for as many as possible. The parties are supposed to report back to the MDL judge sometime this week.
July 18, 2024
There will be a Tepezza settlement mediation this month. It is hard to be optimistic these settlement talks will yield a resolution but hopefully some progress can be made.
July 14, 2024
There is good news and bad news in the Tepezza litigation. The good news the court has set bellwether trial dates:
Bellwether Dates
- First Bellwether Plaintiff Trial (3-4 weeks): March 9, 2026
- Second Bellwether Plaintiff Trial (3-4 weeks): May 4, 2026
- Third Bellwether Plaintiff Trial (3-4 weeks): June 29, 2026
- Fourth Bellwether Plaintiff Trial (3-4 weeks): August 24, 2026
The bad news is obvious – the first trial is still 20 months away. There is talk of an early Tepezza settlement long before we get to 2026. It is rare have an MDL settlement until a trial date gets closer. But the small size of this litigation makes an early settlement possible.
July 1, 2024
The Tepezza MDL continues to grow at a steady rate. Nineteen new lawsuits were added last month. One of those lawsuits, filed last Thursday, was on behalf of a plaintiff from Arvada, Colorado who received three infusions of Tepezza from May 20, 2022, to June 30, 2022, and claims that the drug led to severe and potentially permanent hearing loss.
The plaintiff argues that the manufacturer of Tepezza was aware or should have been aware of the risks associated with the drug. Scientific studies, patient reports, and post-marketing data have indicated that Tepezza can cause significant hearing impairments. Despite this knowledge, the defendant allegedly failed to provide adequate warnings or instructions about the need for audiologic monitoring before, during, and after treatment. It wasn’t until July 17, 2023, that the drug’s label was updated to include warnings about the risk of severe hearing impairments and the necessity of hearing assessments.
June 5, 2024
The first bellwether trial for the Tepezza MDL is set for March 9, 2026. Following this, three additional trials are scheduled, with the second starting on May 4, 2026, the third on June 29 of the same year, and the fourth slated to begin on August 24, 2026.
Is that a long time from now? It is. Unfortunately, this is how mass torts work. Nguyen Injury Lawyer does think there will be a Tepezza settlement before one of these lawsuits goes to trial. Plaintiffs’ lawyers really like these cases, and there is not the volume of cases we thought we would see when this whole thing got started. That will make settlement much easier for Horizon.
June 3, 2024
More slow growth in the Tepezza hearing loss class action MDL. Just 7 new cases were added to the MDL over the last month, which is even less than what we saw in April. There are now 120 total cases in the MDL.
June 2, 2024
Horizon has picked four women as its bellwether selections.
May 20, 2024
The judge in the Tepezza hearing loss MDL recently set a date of March 9, 2026, for the first bellwether trial to begin. Judge Durkin has instructed both sides to collaborate and submit a proposed schedule for how discovery and bellwether case selection should proceed leading up to the bellwether trial.
April 13, 2024
The status hearing originally scheduled for April 22, 2024, before the magistrate judge, has been canceled. The joint status report, previously due on April 18, 2024, is now required to be submitted by April 24, 2024.
Additionally, an in-person status hearing before the Honorable Thomas M. Durkin is scheduled for May 1, 2024, at 1:30 p.m.
April 9, 2024
In a new Tepezza lawsuit, a Florida man alleges he sustained severe injuries due to the infusions of Tepezza.
Diagnosed with eye disease, the man underwent a series of Tepezza infusions from February 25, 2022, to July 29, 2022 in Ohio. Throughout the treatment period, neither he nor his doctors were warned or had any knowledge of Tepezza’s serious risk of causing permanent hearing loss and/or tinnitus. It was not until July 2023 that information about Tepezza’s potential to cause permanent hearing damage became known, with no prior directives for baseline audiology testing or hearing acuity monitoring during treatment. As a result, the plaintiff now suffers from permanent hearing loss and tinnitus due to the Tepezza infusions. Consequently, he is seeking compensation for the permanent injuries sustained from these infusions.
April 1, 2024
The growth in the Tepezza hearing loss class action MDL continues to be very slow. Only 8 new cases were added to the MDL over the last month. That brings the current total of pending cases up to 101. There were 54 pending cases when the Tepezza MDL was created back in August 2023.
March 19, 2024
Oral arguments are tomorrow on the defendants’ effort to slow down the process of getting to bellwether trials. It is hard to imagine the MDL judge will not want to push this litigation forward, but we should know soon enough.
March 13, 2024
Lawyers defending Tepezza for Horizon want to slow things down. They have submitted a request to the MDL judge to postpone for two months the deadline for choosing four lawsuits related to Tepezza hearing loss for early bellwether discovery and potential trial preparation. The company cites the ongoing review of medical records to identify the most suitable cases for this process as the reason for needing more time.
Tepezza Litigation Updates
Defendants invariably seek to slow down litigation. Our strategy is to aggressively pursue these lawsuits towards trial, as that is the most effective path to achieving a Tepezza settlement.
March 1, 2024
There is promising news for patients seeking alternatives to Tepezza. Innovent Biologics has reported successful phase 3 trials for their thyroid eye disease (TED) treatment, IBI311, a direct competitor to Amgen’s Tepezza. The treatment is now on the verge of approval in China.
The trial demonstrated a significant reduction in eyeball protrusion compared to a placebo, with 85.8% of participants showing marked improvement with IBI311. No serious adverse events were reported. Innovent is positioned to promptly apply for new drug approval in China, and potentially in other countries soon.
February 15, 2024
Attorneys involved in the Tepezza litigation reported ongoing disagreement regarding data handling from non-custodial sources. If these issues persist, both sides will submit their arguments to the Court simultaneously by 5:00 p.m. CST on February 28, 2024. The court is expected to resolve these differences at the status conference on March 6th.
February 8, 2024
An agreement has been reached concerning Horizon’s document production in the Tepezza hearing loss lawsuits. However, the full production will not be completed until the end of the year, which may temper expectations for a quick Tepezza settlement in 2024.
Access to Horizon’s internal documents is critical. Attorneys for plaintiffs in Tepezza lawsuits believe these documents will reveal what Horizon knew about Tepezza’s risks and when they knew it. Effective discovery will be crucial to uncovering emails, meeting minutes, and internal studies that could prove knowledge and liability.
While there is speculation that this MDL could settle sooner than expected, it is important to maintain pressure on Horizon to ensure a fair resolution.
January 15, 2024
Since mid-December, three new hearing loss cases have been added to the Tepezza MDL, bringing the total to 74. (The actual number is 75, including the case of Ingram v. Horizon, filed in 2024 but not yet included in the MDL count.)
As Nguyen Injury Lawyer has stated previously, this litigation is not expected to be massive. This is ultimately beneficial for victims, as it should facilitate a faster settlement process with a higher average settlement amount compared to a scenario with thousands of plaintiffs.
January 9, 2024
Attorneys in the Tepezza hearing loss litigation have jointly requested a 60-day extension from the U.S. District Judge to review medical records and other critical documents. This extension is necessary for more effective identification of cases for the Initial Bellwether Discovery Pool.
Judge Durkin initially allocated 60 days for the plaintiffs to select four cases and 90 days for the defendants to select four cases for this initial pool. Following these selections, the parties were to collaborate on finalizing a list of remaining eligible Tepezza lawsuits, from which the Court would randomly pick four additional cases, bringing the total to 12. However, in a joint agreement submitted on January 2, 2024, both sides agreed that a 60-day extension was needed for selecting the bellwether cases.
January 8, 2024
The litigation was centralized before Judge Thomas Durkin on June 25, 2023. The slow progress of this MDL, as noted in the latest CMC, needs to accelerate.
Tepezza plaintiffs’ attorneys are actively addressing this. They filed a motion opposing Horizon’s request to postpone a case management conference, arguing that there are disputes, such as the unresolved Production Protocol, that require the Court’s intervention.
These conferences advance the litigation. Defendants often seek to stall, and delaying the CMC would only prolong the MDL’s slow pace. We hope that the status conference proceeds as planned, with a ruling from the judge expected soon.
December 18, 2023
Twelve new cases were transferred into the Tepezza hearing loss MDL over the past month, bringing the total to 71. This increase could signal a growth trend as we enter 2024.
December 1, 2023
An early discovery dispute is developing in the Tepezza hearing loss MDL. Plaintiffs’ lawyers recently filed a “Narrative Submission” outlining complaints about Horizon’s compliance with initial discovery issues and requests.
November 20, 2023
A Florida woman has joined the Tepezza hearing loss litigation. She alleges that she received Tepezza infusions for thyroid eye disease from August 2022 to April 2023 and subsequently suffered permanent hearing loss and tinnitus. Her lawsuit claims that Horizon Therapeutics negligently failed to warn her and her doctor about the risk of hearing damage associated with Tepezza. If you have suffered hearing loss, contact Nguyen Injury Lawyer at XXX-XXX-XXXX for a free consultation.
November 19, 2023
Only five new cases were transferred into the Tepezza hearing loss MDL over the past month, bringing the total to 59. This slow growth in the first three months of the MDL is, in many ways, beneficial for victims, as a smaller pool of plaintiffs can make settlement easier and faster to achieve.
November 6, 2023
Lawyers representing Tepezza victims successfully opposed a motion to dismiss claims alleging that Horizon should have developed a safer version of Tepezza before seeking FDA approval. The plaintiffs argue that the drug is linked to hearing loss. The court ruled that federal law does not preempt these “pre-approval” design defect claims.
The plaintiffs argued that Horizon had a duty under state law to propose a formulation that did not cause permanent hearing damage. The court found that federal law did not dictate Horizon’s design choices at this stage, allowing the state-law claim to proceed.
November 3, 2023
The judge in the Tepezza hearing loss MDL issued a new Case Management Order outlining the rules and procedures for the bellwether case selection process and trials. An initial pool of 12 bellwether candidate cases will be selected within 60 days, with each side selecting 4 cases and the remaining four being randomly selected. These 12 cases will then undergo a fact-discovery process.
September 18, 2023
In June, 41 cases were pending in the Tepezza MDL. As of this week, there are 54, a comparatively small increase. The volume of new cases is expected to increase considerably moving forward.
September 14, 2023
Magistrate Judge M. David Weisman is now overseeing the Tepezza class action to manage the discovery process, including modifying the discovery deadline and overseeing settlement conferences.
The preliminary status hearing is scheduled for September 19, 2023, at 9:15 a.m. The conference call-in number is 1-877-411-9748, and the passcode is 1814539. (Note: recording is prohibited by court rules.)
September 11, 2023
Amgen Inc. has reached an agreement with the FTC to proceed with its $27 billion acquisition of Horizon Therapeutics. The acquisition was previously halted due to antitrust concerns. With the deal back on, Amgen will assume liability for the Tepezza hearing loss claims, a positive development for plaintiffs as Amgen has greater financial resources to cover any eventual settlement.
September 10, 2023
A status hearing in the Tepezza class action lawsuit took place on Friday, September 8, 2023.
Tepezza lawyers were directed to submit a proposed agreed order concerning matters related to 502(d) and privileged materials, along with a protective order to the Court. This allows Horizon’s lawyers to share documents or information during discovery without waiving attorney-client privilege or work-product protection.
The Honorable M. David Weisman will assist the MDL judge in handling various aspects of this lawsuit, including overseeing discovery and facilitating potential settlements.
September 1, 2023
Plaintiffs in the Tepezza MDL are advocating for a fast schedule to reach the first round of bellwether trials as soon as possible.
In the proposed bellwether schedule submitted by the plaintiffs’ lawyers, each side would select three bellwether candidate cases for a 150-day case-specific discovery phase.
Following this discovery period, three of the six lawsuits will be selected for the first test trials. Horizon Therapeutics’ defense counsel proposed a slightly larger pool of 10 cases for bellwether discovery.
August 18, 2023
A new Tepezza lawsuit – Mhamdi v. Horizon Therapeutics USA, Inc. – was directly filed this week in the MDL 3568 by a Florida woman alleging severe injuries resulting from Tepezza infusions.
The plaintiff was diagnosed with thyroid eye disease and/or Graves’ Disease and received Tepezza infusions from August 2020 through February 2023. She now suffers from permanent hearing loss and/or tinnitus.
Her Tepezza suit alleges that she and her physicians were not warned about the severe risk of permanent hearing loss or tinnitus posed by Tepezza. If you or a loved one has experienced hearing loss after Tepezza treatment, contact Nguyen Injury Lawyer at XXX-XXX-XXXX.
August 15, 2023
Five new Tepezza hearing loss cases were transferred into the new Tepezza MDL over the past month, bringing the total to 46 for an MDL only three months old. While this may not become a huge class action, we could quickly reach 100 cases by the end of the year. Our attorneys are very optimistic about these cases. (Update: we reached 73 in 2023.)
August 2, 2023
We are awaiting the first major scheduling order in the new Tepezza class action MDL. The stream of new incoming Tepezza hearing loss lawsuits has been intermittent. Only three new Tepezza cases were filed in July, while June saw the highest volume to date with 16 new cases filed.
July 25, 2023
Amid mounting lawsuits against Horizon Pharmaceuticals over allegations of Tepezza-induced hearing loss, the company is under scrutiny for purportedly failing to adequately warn consumers and the medical community about the associated risks of their thyroid eye disease medication. Contact Nguyen Injury Lawyer today for a free consultation: XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com/contact.
Government agencies are increasing their efforts to protect patients. The FDA has updated its warning for Tepezza to include stronger language indicating the drug may cause severe and irreversible auditory damage.
In the Elmiron litigation, settlement amounts were lower for patients who continued using the drug after the new warning was issued. If you are considering a Tepezza lawsuit, consult your doctor about whether you should stop taking the drug. Your health is more important than any potential legal claim.
June 19, 2023: On June 28, 2023, the judge assigned to oversee the new Tepezza class action MDL will hold an initial status conference with all parties and their attorneys. This meeting will be Judge Durkin’s first opportunity to familiarize himself with the litigation and establish a plan for managing the Tepezza hearing loss lawsuits collectively. Judge Durkin will also outline the process for selecting individual lawyers to serve on the plaintiffs’ steering or executive committee for the litigation.
June 5, 2023: It is now official. A new Tepezza class action lawsuit has been filed against Horizon Therapeutics USA Inc. The lawsuit alleges that the company failed to adequately warn about the potential for hearing loss and tinnitus caused by Tepezza. The MDL Panel has consolidated the cases, and Judge Thomas M. Durkin of Chicago will preside over this class action (technically an MDL, not a class action). Our legal team at Nguyen Injury Lawyer is confident in the strength of these lawsuits. We anticipate that victims will receive fair settlement compensation, particularly now that plaintiffs will have a jointly organized plan to pursue discovery and coordinate their Tepezza lawsuits.
May 31, 2023: A new Tepezza lawsuit was recently filed in Ohio. The plaintiff was diagnosed with thyroid eye disease (Graves’ disease) and received Tepezza infusions from April 2021 through October 2021. The lawsuit alleges that neither the plaintiff nor their physicians were warned about the significant risk of permanent hearing loss and/or tinnitus associated with Tepezza during this period. The plaintiff now suffers from permanent hearing loss (and/or tinnitus).
May 22, 2023: As the JPML prepares to hear oral arguments on the creation of a new class action MDL, the number of new Tepezza hearing loss cases continues to rise. Ten new Tepezza lawsuits were filed in federal courts in the past week. Meanwhile, Amgen’s acquisition of Horizon Therapeutics may be in jeopardy after the Federal Trade Commission sought an injunction to block the $27 billion deal.
May 11, 2023: As previously reported, the Judicial Panel on Multidistrict Litigation (JPML) will hold a hearing on May 25, 2023, to determine whether the Tepezza cases in federal courts should be consolidated into a class action MDL, due to the increasing number of Tepezza hearing loss lawsuits.
Horizon Therapeutics has filed a motion opposing MDL consolidation, arguing that it is not warranted because there are not enough pending cases. Horizon also suggests that the number of Tepezza lawsuits filed in the future will be limited.
May 8, 2023: The rate at which new Tepezza hearing loss lawsuits are being filed across the country has increased significantly in the last six weeks. When a motion seeking MDL consolidation was filed in March, it listed only 18 Tepezza cases pending in 5 different federal districts. Since then, seven more Tepezza hearing loss lawsuits have been filed in federal courts. The JPML is scheduled to consider whether to create a new class action MDL at the end of this month.
April 26, 2023: The Multidistrict Litigation (MDL) panel, also known as the U.S. Judicial Panel on Multidistrict Litigation (JPML), is a group of federal judges responsible for deciding whether to consolidate and centralize civil cases involving similar questions of fact that have been filed in multiple federal courts.
The panel aims to streamline and coordinate pretrial proceedings, promote efficiency, avoid duplicate discovery, and prevent inconsistent rulings. On May 25, 2023, this panel of judges will decide whether to create a Tepezza class action lawsuit to consolidate all federal court cases under a single judge.
April 14, 2023: While more Tepezza lawsuits are filed and we await a ruling on the possibility of a class action lawsuit, Horizon continues to seek ways to increase profits from Tepezza. Horizon Therapeutics recently announced new FDA approval for an amendment to the indication language for Tepezza, expanding the circumstances under which the drug can be used to treat Thyroid Eye Disease (TED) patients.
This change follows a Phase 4 clinical trial that showed positive results, with patients receiving Tepezza experiencing a significant reduction in proptosis at Week 24 compared to those given a placebo. The revised indication intends to offer unrestricted access to all eligible patients throughout the entire range of TED, potentially easing the access burden for patients and doctors and shortening the time to treatment. The company plans to present the Phase Four trial data at an upcoming medical congress and publish the findings in a peer-reviewed medical journal.
For drug companies, settlement payouts and jury awards are often a small fraction of the billions they can generate. Horizon could potentially withstand a successful Tepezza class action lawsuit and still realize a substantial profit from the drug.
April 13, 2023: A motion has been filed to consolidate the hearing damage lawsuits into a single Tepezza class action lawsuit for federal court claims. The motion was filed with the Judicial Panel on Multidistrict Litigation (JPML) and lists 18 pending Tepezza product liability cases across five different federal districts. If the MDL is granted, the movants request that the venue be the Northern District of California.
April 4, 2023: A research team from Stanford University recently published a new case study report indicating that hearing loss is directly related to the dosage levels of Tepezza injections. The case study involved a 64-year-old woman who received a full round of Tepezza injections in 2021. She experienced significant side effects, including hearing loss in both ears, immediately after the injections. Her hearing problems subsided when she stopped receiving the injections. A year later, her doctors administered another round of Tepezza injections at a much lower dose, and the woman did not experience the same hearing loss issues as before. The case study provides further evidence of a clear and direct link between Tepezza and hearing loss.
March 24, 2023: Since the beginning of March, four new lawsuits have been filed in federal courts alleging that Tepezza injections caused permanent hearing damage. To date, a total of 34 Tepezza hearing loss lawsuits have been filed in federal courts. Voluntary dismissals were filed in 13 of those cases, suggesting that they may have been settled.
February 28, 2023: What a Tepezza hearing loss suit looks like.
February 14, 2023: Horizon Therapeutics, the maker of Tepezza, is seeking to dismiss the Tepezza hearing loss claims against it based on the doctrine of federal preemption. Preemption motions are common in product liability cases, particularly those involving claims of failure to warn about prescription drug risks. Horizon’s motion to dismiss argues that the tort claims asserted by the Tepezza plaintiffs are preempted by federal law because the FDA regulated Horizon’s ability to change the warning label for Tepezza.
January 20, 2023: Lawyers representing Tepezza plaintiffs have filed a motion to consolidate 10 Tepezza hearing loss cases currently pending in the Northern District of Illinois. The request seeks to consolidate these 10 cases before a single judge.
The result would be similar to a “local MDL class action lawsuit” within the federal district and would apply only to these ten Tepezza hearing loss suits (and possibly more in the future).
Horizon has filed an opposition, arguing that each Tepezza lawsuit involves significantly different factual allegations. Fewer than 20 Tepezza product liability claims are pending in federal courts, including ten in Illinois.
January 18, 2023: Amgen, a large biopharmaceutical company, announced a deal to acquire Horizon Therapeutics (the maker of Tepezza) for $116.50 per share. However, a group of Amgen investors has filed suit to block the sale, citing concerns about claims that Horizon withheld information about the risk of hearing damage associated with Tepezza.
This is a positive development for those considering a Tepezza lawsuit.
Tepezza
Tepezza (teprotumumab-trbw) is a prescription medication used to treat thyroid eye disease (TED), a rare autoimmune disorder causing inflammation and swelling of the tissues around the eyes. Tepezza is the first and only FDA-approved medication for this condition. It functions by blocking the activity of the insulin-like growth factor 1 receptor (IGF-1R), which is believed to be involved in the development of TED. Tepezza is administered intravenously (IV) over three to six months and has been shown to improve symptoms such as eye bulging, double vision, and eye pain in patients with active TED.
Tepezza inhibits (or blocks) the activity of the protein insulin-like growth factor-1, which is thought to play a significant role in the development of the disorder. Horizon Therapeutics developed Tepezza, and it remains under its original patent protection. Tepezza is administered via injections.
In January 2020, the U.S. Food and Drug Administration (FDA) approved Tepezza, making it the first approved drug indicated to treat thyroid eye disease.
In addition to the serious risk of hearing loss, which is the subject of this litigation, Tepezza is associated with several other side effects that patients should be aware of. The most commonly reported side effects include muscle spasms, nausea, diarrhea, fatigue, dry skin, and headaches. Some patients also experience an altered sense of taste, causing certain foods to taste metallic or different than usual.
Tepezza is also known to cause an increase in blood sugar levels, which may be problematic for patients with diabetes or those at risk of developing high blood sugar. Swelling, particularly in the hands and feet, is another commonly reported side effect. Additionally, some patients may experience high blood pressure during treatment.
While most of these side effects are mild and temporary, they can still affect a patient’s quality of life during treatment. Patients should discuss any side effects with their healthcare provider, as some may require additional management or monitoring while on Tepezza. Being aware of the full range of potential risks allows patients to make informed choices about their treatment options. This is where the hearing loss and tinnitus issue becomes relevant, which we will address shortly. If you have concerns about Tepezza, please contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit https://www.nguyeninjurylawyer.com.
Graves Disease
Thyroid Eye Disease (TED) is characterized by the progressive inflammation of the tissues surrounding the eyes, leading to symptoms like red, swollen eyelids and discomfort, with the eyes sometimes bulging outwards (proptosis). Despite Horizon Therapeutics’ promotional materials suggesting that vision impairment is common among those with TED, severe outcomes are actually quite rare, affecting only 3–5% of those with the condition. Despite this, Horizon promoted Tepezza for use in anyone diagnosed with TED, advocating for its early treatment. Contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit our contact page at https://www.nguyeninjurylawyer.com/contact if you have been affected.
Understanding Thyroid Eye Disease (TED) and Its Link to Tepezza-Related Hearing Loss
Thyroid Eye Disease (TED) is an autoimmune condition often associated with hyperthyroidism, though the exact mechanisms are still being researched. The severity of TED symptoms varies considerably among individuals, ranging from mild to debilitating. Common symptoms include redness, irritation, and discomfort in the eyes and eyelids, dry eyes, pain with eye movement, and eyelid retraction.
One of the most prominent symptoms is exophthalmos or proptosis, characterized by bulging of the eyes. Additional symptoms may include blurred vision, double vision (diplopia), eye misalignment (strabismus), chronic bloodshot eyes, swelling around the eyelids, light sensitivity, and difficulty moving the eyes.
TED typically progresses through two phases: an “active phase,” during which symptoms worsen and inflammation is evident, and an “inactive phase,” where the condition stabilizes. The active phase usually lasts from six months to two years.
TED is most frequently linked to Graves’ disease, an autoimmune disorder that affects the thyroid, skin, and eyes. However, it can also occur in individuals with overactive or underactive thyroids. For mild TED cases, treatment options include supportive measures such as dark sunglasses, ointments, artificial tears, or prism glasses. Corticosteroids may be prescribed to reduce inflammation in moderate to severe cases. Surgical intervention may be considered for individuals with moderate to severe TED, typically after the active phase has concluded.
The 2008 Consensus Statement from the European Group on Graves’ Orbitopathy (EUGOGO) on the Management of Graves’ Orbitopathy suggests that TED is often mild, self-limiting, and potentially decreasing in frequency, with only a small percentage of cases posing a threat to eyesight. Therefore, medication for Graves’ disease requires careful balancing of risks and benefits, underscoring the importance of understanding all potential risks associated with any drug.
Studies Linking Tepezza to Serious Hearing Loss
Numerous studies and reports have established a connection between Tepezza use and hearing loss, as well as other hearing-related complications.
A small study presented at the ENDO 2021 conference revealed that 65% of patients taking Tepezza reported otologic symptoms, including hearing loss, tinnitus, ear plugging sensation, and autophony (hearing one’s own voice unusually loud). This rate is significantly higher than the 10% reported in earlier clinical trials. These symptoms often manifested after an average of 3.6 infusions. Among patients experiencing new hearing symptoms, some exhibited new or worsening sensorineural hearing loss, a type of hearing loss resulting from damage to the inner ear’s hair cells.
Moreover, a report published in The Annals of Otology, Rhinology, and Laryngology described a case of significant hearing loss in a patient following Tepezza treatments, with symptoms persisting despite discontinuing the drug and undergoing treatment with oral corticosteroids.
The American Journal of Ophthalmology highlighted the long-term impact of Tepezza on hearing function, revealing that only a fraction of patients who experienced subjective hearing loss or decreased word comprehension made a full recovery after eight months of discontinuing Tepezza infusions.
A case series of four cases of Tepezza-associated hearing loss was reported based upon patients of three doctors who treated 28 patients. The authors proposed a mechanism for how Tepezza was causing hearing damage.
Contrary to public statements, patients and doctors began reporting severe ear complications and permanent hearing problems soon after the FDA approved Tepezza. Emerging research indicated that Horizon not only grossly understated the risk of hearing damage associated with Tepezza but also downplayed the severity of such damage.
According to reports and plaintiffs’ lawsuits, concerns were raised internally at Horizon by employees, including Dr. Wenzhong “Jerry” Liu, regarding hearing loss linked to Tepezza use.
Despite clinical trial data and subsequent analyses indicating a higher rate of hearing impairment than initially reported, Horizon continued to minimize these risks. The company maintained that most hearing-related adverse events observed in pivotal trials and post-approval were minor to moderate and reversible.
Dr. Liu, with extensive experience in clinical development and medical affairs, questioned the accuracy of the reported 10% incidence rate of hearing impairment, suggesting that findings from later studies, including Study 401 (EAP), indicated a much higher rate. He advocated for disclosing this updated data to regulatory agencies, healthcare professionals, and the public, emphasizing that the true frequency of serious hearing impairment was significantly higher than the label suggested.
Despite Dr. Liu’s suggestions to share the findings from Study 401, which showed a 40% incidence rate of hearing impairment, and his ongoing concerns about the accuracy of public disclosures on hearing impairment risks, he was eventually dismissed from his position. Dr. Liu subsequently filed a wrongful-termination lawsuit against Horizon.
Horizon’s Alleged Failure to Adequately Warn About Hearing Loss Risks
Although Horizon acknowledged hearing loss as a potential side effect of Tepezza, lawsuits allege that this warning was inadequate because it grossly understated the level of risk. A warning that does not meaningfully convey the risk is effectively no warning at all.
Horizon allegedly knew or should have reasonably known that Tepezza presented a much higher risk of hearing loss, and that this hearing loss could be permanent. Ample medical literature suggested that IGF-I plays a central role in hearing and that low levels of IGF-I are associated with hearing loss. Horizon arguably should have known this when Tepezza was submitted for FDA approval. At the very least, however, Horizon became aware of these issues with Tepezza shortly after the drug was approved, as reports and studies linking it to hearing damage began to emerge.
Tepezza Hearing Loss Lawsuits
In 2022, individuals who suffered hearing loss or tinnitus after receiving Tepezza injections began filing product liability lawsuits against Horizon. These lawsuits allege that Horizon negligently failed to adequately warn patients and doctors about the real risks of hearing damage associated with Tepezza.
Plaintiffs in Tepezza lawsuits in the MDL claim that the lack of an adequate warning about the risk of hearing damage from Tepezza left them and their doctors unaware of the potential harm the drug could cause. They further allege that they would not have taken Tepezza for their TED treatment had Horizon provided an adequate and accurate warning about this risk.
Over 175 Tepezza lawsuits have been filed in the MDL, and more are anticipated. This litigation is now part of a class action MDL.
Potential Settlement Payouts for Tepezza Hearing Loss Lawsuits
It is still premature to predict the exact worth of a Tepezza lawsuit in a future settlement due to the many variables at play and the early stage of the litigation. This is especially true as updates continue to unfold in the Tepezza MDL, and new information emerges from ongoing discovery and expert evaluations. At this point, it is difficult to say with certainty whether these Tepezza hearing loss lawsuits will be viable across the board, particularly as defense lawyers push back against causation claims.
That said, mass tort lawyers following this litigation closely are optimistic. Many believe that if liability is established, the settlement amounts in the Tepezza class action lawsuit could be significant. Based on the current facts, a rough estimate of what a successful case might look like in terms of compensation can be offered.
Nguyen Injury Lawyer estimates that a Tepezza hearing loss lawsuit with strong facts could result in an average settlement payout ranging from $140,000 to $350,000. The exact amount will vary widely depending on several factors, including the plaintiff’s age, the extent and permanence of the hearing loss, and any preexisting hearing conditions. Cases involving major, irreversible hearing loss in younger plaintiffs may result in much higher settlement payouts.
As the Tepezza lawsuit progresses, Nguyen Injury Lawyer expects to refine these estimates and gain a better understanding of how judges and juries respond to the evidence. We believe these are strong claims that will perform well in front of a jury and that Horizon will likely settle most of these cases before they reach trial.
Hearing Loss Settlements and Verdicts
One of the best ways to accurately predict the potential settlement value of tort cases is to look at prior settlements and trial verdicts in cases involving the same type of injury. Below are summaries of prior verdicts and reported settlements in cases in which the plaintiff’s primary injury was hearing loss or tinnitus. Most of these are verdicts from the recent bellwether trials in the 3M earplugs class action. For these verdicts, we are excluding the amount of punitive damages awarded and only listing the amount of compensatory damages.
- Beal v 3M Co. (Florida 2022) $72,500,000: The last of 16 bellwether test trials in the 3M earplugs class action resulted in a verdict of $72.5 million in punitive damages and $5 million in compensatory damages for hearing loss suffered by an Army veteran. These 3M verdicts are telling because they involve hearing loss lawsuits against a large company for failure to warn, a good comparable.
- Vaughn v 3M Co. (Florida 2022) $2,200,000: 3M earplug bellwether verdict from April 2022 in which veteran was awarded $2.2 million in compensatory damages for hearing loss allegedly caused by defective earplugs.
- M. v Viola (New York 2020) $250,000: A 2-year-old suffered permanent hearing loss from injuries in a car accident. The case settled for $250,000, which was likely the available insurance limit and would have been worth more had it not been.
- Luoma v State Farm (Washington 2020) $126,025: A 60-year-old plaintiff injured in an auto accident alleged permanent hearing loss. The jury awarded $101,025, and he received another $25,000 in a settlement payout before trial.
Recent Tepezza Lawsuits
A pair of Tepezza hearing loss lawsuits were recently filed in the U.S. District Court for the Northern District of Illinois (Chicago). The first case, Weibel v. Horizon Pharmaceuticals, Inc. (1:22-cv-4518), was followed by a second case, Nethery v. Horizon Pharmaceuticals Inc. (1:22-cv-5005) two weeks later.
Both cases involve nearly identical factual allegations. Both plaintiffs were diagnosed with TED and prescribed a full series of Tepezza infusions by their doctor over four months. Both plaintiffs further allege that shortly after the Tepezza infusions they suffered major hearing loss and tinnitus. The Complaints alleged that the doctors were given no warning about the risk of hearing loss.
Lawyers for Horizon filed an identical Motion to Dismiss.
If you or a loved one has experienced hearing loss or other auditory issues after undergoing Tepezza treatment, please contact Nguyen Injury Lawyer at XXX-XXX-XXXX or visit our website at https://www.nguyeninjurylawyer.com. You can also reach us through our contact page at https://www.nguyeninjurylawyer.com/contact for a free and confidential consultation. Our attorneys are here to help you understand your legal options and pursue the compensation you deserve.
Defense Attempts to Dismiss Tepezza Hearing Loss Claims
In both Tepezza hearing loss cases, the defendant filed a motion to dismiss. This motion, a concise two-page document, asserts that the plaintiffs’ failure-to-warn claims should be dismissed based on the federal preemption doctrine. This argument, common in pharmaceutical tort cases, suggests that Tepezza’s warning labels are governed by federal law and regulations that supersede state law tort claims.
However, this argument was unsuccessful. Federal preemption arguments in drug cases often fail because federal law and FDA regulations allow drug companies to update their warning labels without FDA approval if new risk evidence emerges. This is precisely the allegation in the Tepezza cases.
In these and all Tepezza lawsuits, attorneys must establish a direct link between Tepezza and hearing loss. Nguyen Injury Lawyer will use strong scientific evidence and expert testimony to demonstrate that Tepezza directly caused the hearing impairments. This involves gathering detailed medical records, expert analyses, and potentially conducting independent studies to support claims of hearing damage due to Tepezza.
How Does Tepezza Cause Hearing-Related Complications?
The exact mechanism by which Tepezza may cause hearing issues is not fully understood. However, some experts believe it is related to its immunomodulatory effects, which might inadvertently affect the inner ear or auditory pathways.
Tepezza functions by inhibiting the insulin-like growth factor-1 receptor (IGF-1R), which is involved in the inflammatory processes of TED. This inhibition modulates the immune response, potentially impacting various body systems, including the auditory system. Experts suggest that these immunomodulatory effects could inadvertently affect the inner ear or auditory pathways, leading to hearing issues.
This could involve an inflammatory response within the ear. By altering the immune system’s function, Tepezza could potentially trigger inflammation that impacts hearing structures, such as the cochlea, auditory nerve, or Eustachian tube.
Contact Us About a Tepezza Hearing Damage Lawsuit
Nguyen Injury Lawyer is currently accepting Tepezza hearing damage lawsuits nationwide. If you took Tepezza for TED treatment and subsequently suffered hearing damage, hearing loss, or permanent ringing in the ears (tinnitus), contact our office today for a free consultation. Call us at XXX-XXX-XXXX or contact us online for a free consultation.
See Also: